Clinical Trial Update: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating Osimertinib alone or in combination with chemotherapy for EGFR-mutant metastatic non-small cell lung cancer and is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING